Item 7.01 Regulation FD Disclosure
On
The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, the presentation referenced above and the other content on our website, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 8.01 Other Events
On
GreenLight today is sharing the key pillars of its human health strategy:
•
Developing vaccines for infectious diseases, especially those addressing unmet medical needs in lower- and middle- income countries. Consistent with its public benefit corporation status, Greenlight is striving to support global, sustainable vaccine access and pandemic response readiness.
•
Developing innovative products to address unmet medical needs in oncology and autoimmune diseases. This work has begun with the collaboration with EpiVax Therapeutics to co-develop personalized cancer vaccines.
•
Continued advancement of GreenLight's mRNA technology platform through innovations and to seek potential partnerships withpharmaceutical and biotechnology companies.
As previously announced, GreenLight received approval from the
Regarding its Shingles program, GreenLight is excited to share new pre-clinical data. GreenLight has selected a lead candidate to progress towards clinical development after evaluation of multiple antigen designs and formulations in animal studies. Based on immunological response evaluations in pre-clinical studies:
•
All mRNA-LNP vaccine candidates tested were highly immunogenic and induced high levels of antigen-specific binding antibodies and strong cellular (T cell) responses:
o
Lead vaccine candidate induced antibody levels similar to comparator vaccine (current standard of care)
o
Lead vaccine candidate was more potent than comparator vaccine at inducing strong cellular immune response
•
Lead vaccine candidates maintained memory B and T cells responses at levels similar to comparator vaccine, 3 months after vaccine candidate administration, demonstrating durability of the immune response.
Forward-Looking Statements
Certain statements in this Current Report on Form 8-K may constitute
"forward-looking statements" for purposes of the federal securities laws. Our
forward-looking statements include, but are not limited to, statements regarding
our or our management team's expectations,
--------------------------------------------------------------------------------
hopes, beliefs, intentions or strategies regarding the future, including those
relating to the success, cost and timing of our research and development
activities in our plant and human health programs, the timing of regulatory
submissions and approvals, our ability to progress our candidates into the
clinic, if at all, the timing to commence future clinical trials, our ability to
commercialize our products, the acceptance of RNA-based technologies by
regulators and the public, our ability to raise and productively deploy capital
and the rate at which we can successfully bring products to market, our
projected cash runway and our ability to obtain funding for our operations when
needed. Forward-looking statements include statements relating to our management
team's expectations, hopes, beliefs, intentions or strategies regarding the
future. In addition, any statements that refer to projections, forecasts or
other characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking statements. The words "anticipate,"
"believe," "contemplate," "continue," "could," "estimate," "expect," "intends,"
"may," "might," "plan," "possible," "potential," "predict," "project," "should,"
"will," "would" and similar expressions may identify forward-looking statements,
but the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements are based on current
expectations and beliefs concerning future developments and their potential
effects. There can be no assurance that future developments affecting us will be
those that we have anticipated. These forward-looking statements involve a
number of risks, uncertainties (some of which are beyond our control) or other
assumptions that may cause actual results or performance to be materially
different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, those factors
described under the heading "Risk Factors" in the Company's most recent Annual
Report on Form 10-K filed with the
--------------------------------------------------------------------------------
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Description
99.1 Press Release issued by
104 Cover Page Interactive Date File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source